Managing Partner – Sector Advisory — Commercial Launch Organisation

The mandate

An advisory partnership is planning succession for the leader of its pharmaceutical sector practice. Clients increasingly need to change launch and market plans when late-stage evidence narrows a label, delays filing or alters differentiation. The replacement Managing Partner must build a practice capable of challenging a board's preferred story while still helping management make executable choices.

Approximately 750 employees and material partners sit across strategy, commercial, medical, market access, data, transactions and transformation advisory. The Managing Partner reports to the Global Managing Partner and regional partner council and owns sector thesis, client portfolio, engagement risk, economics, talent and reputation.

The sector proposition will link development evidence to launch operations. Teams should understand endpoint, comparator, population, safety and regulatory uncertainty before recommending positioning, investment or field scale. The practice will not treat a clinical assumption as a commercial fact simply because it appears in a client's base case.

Launch scenarios need operational detail. Label, approval timing, payer evidence, supply, diagnostic pathway, medical capability and country sequence affect value. The Managing Partner will ensure advisers model decision triggers and reversible commitments rather than give one deterministic launch forecast.

Portfolio reprioritisation requires enterprise trade-offs. A late-stage programme may need another study or a narrower market; another asset may deserve accelerated investment. Engagements will show marginal capital and scarce capability across assets. Protecting every project is not a strategy recommendation.

Market access advice must be evidence-led and country-aware. Payers can value comparative outcomes, budget impact and implementation differently. Teams will distinguish legitimate insight from unsupported willingness-to-pay assumptions. Proposed outcomes arrangements need measurable data and deliverable operating systems.

Medical-commercial boundaries are critical. Advisers may support organisation and process but cannot shape scientific conclusions to fit a launch narrative. Qualified clinical and regulatory professionals will review relevant work. Recommendations will state uncertainty and permitted use, especially before approval.

Origination should begin with a consequential client decision. The partner will avoid broad transformation pursuits that expand after a vague diagnostic. Proposal acceptance will test sponsorship, evidence access, conflicts, clinical review and management authority. Work will be declined when a predetermined answer is the true brief.

Independence matters across pharmaceutical ecosystems. The practice may advise manufacturers, investors, payers and suppliers. Conflict review should consider data, mechanisms, trials and market strategy, not only corporate entity. Information barriers or refusal may be required despite revenue.

Engagement economics will support senior and specialist work. Underpriced strategy followed by junior implementation can damage decision quality. Scope should define decisions, evidence, outputs, client owners and outcome verification. Change requires explicit agreement.

Value claims will remain modest and attributable. Advisory work can influence capital, timing or operating design, but clinical success belongs to the asset and management. Benefits registers should state baseline and adviser contribution. Public case studies need client permission and cannot reveal disguised competitive insight.

The practice needs succession beyond the incumbent. Emerging partners will receive substantive account and board ownership, not ceremonial exposure. Compensation and staffing should reward collaboration. The Managing Partner will document methods while encouraging judgement rather than rigid playbooks.

The Dublin base will connect European regulatory, tax and launch expertise with global clients. Country practitioners should shape recommendations, and local differences should not be forced into a generic model. The leader will build a network of clinical, access and supply specialists who can mobilise quickly.

What you will own

• Pharmaceutical sector and launch advisory thesis.
• Board origination and client stewardship.
• Evidence-led launch and portfolio methods.
• Engagement acceptance, conflict and clinical review.
• Economics, quality and outcome verification.
• Regional specialist network and intellectual capital.
• Account transition and partner succession.
• Practice contribution and reputation.

The first 12 months

Within 60 days, review the inherited client book, conflicts, live work and relationship concentration. Agree transitions and correct any engagement whose launch assumptions exceed evidence.

By month six, publish the sector thesis, launch two evidence-to-launch propositions and place emerging partners in priority board relationships. Introduce independent outcome reviews.

At twelve months, deliver EUR 85 million of quality-reviewed revenue at target contribution, with 70% of priority accounts under shared partner ownership. At least ten engagements should show verified client decisions or operating outcomes, with no material independence, confidentiality or scientific-boundary breach.

What the council will test

• Launch advice changing when clinical evidence changes.
• Scenarios including regulatory and operating triggers.
• Portfolio work forcing real capital choices.
• Clinical conclusions remaining independently owned.
• Conflicts assessed across assets and ecosystems.
• Client trust transferring beyond the incumbent.

The person

You bring 28+ years in pharmaceutical strategy, commercial leadership, market access or top-tier advisory. Your record includes board origination, late-stage portfolio choices and launch work across international markets. You have led a significant partner and specialist community.

Candidates must show advice that contradicted the preferred launch case and account succession beyond personal relationships. Dublin is the onsite base with extensive global client travel.

Compensation and terms

Base compensation is EUR 410,000–590,000 plus annual incentive and long-term participation linked to sector contribution, client decisions, independence, quality and partner succession. The onsite Dublin advisory role reports to the Global Managing Partner and regional partner council. Planned replacement supports orderly client transfer.

Confidentiality

The partnership, clients, assets, trials, evidence, methods, advisers and succession arrangements remain confidential. More information follows conflict review and signed confidentiality. Applicants must not approach pharmaceutical boards or advisers to infer the hiring organisation.